515160-72-2

Basic information

• Product Name: 1-[4-(2-METHOXY-ETHOXY)-PHENYL]-PIPERAZINE
• Synonyms: 1-[4-(2-METHOXY-ETHOXY)-PHENYL]-PIPERAZINE;Piperazine, 1-[4-(2-Methoxyethoxy)phenyl]-;1-[4-(2-METHOXY-ETHOXY)-PHENYL]-PIPERAZINE hydrochloride
• CAS NO: 515160-72-2
• Molecular Formula: C₁₃H₂₀N₂O₂
• Molecular Weight: 236.31
• Mol File: 515160-72-2.mol

Chemical Properties

• Boiling Point: 383.249°C at 760 mmHg
• Flash Point: 185.583°C
• Appearance: /
• Density: 1.069g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.523
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 9.00±0.10(Predicted)
• CAS DataBase Reference: 1-[4-(2-METHOXY-ETHOXY)-PHENYL]-PIPERAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-[4-(2-METHOXY-ETHOXY)-PHENYL]-PIPERAZINE(515160-72-2)
• EPA Substance Registry System: 1-[4-(2-METHOXY-ETHOXY)-PHENYL]-PIPERAZINE(515160-72-2)

Safety Data

• Hazardous Substances Data: 515160-72-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
TFMPP is used as a research chemical for the development of drugs targeting the 5-HT2 receptor. Its psychoactive properties make it a valuable tool in studying the effects of serotonin receptor agonists on mood, perception, and cognition.
Used in Recreational Drug Use:
TFMPP is used as a recreational drug due to its psychoactive effects, which include heightened sensory perception, altered sense of time, and hallucinations. However, it is considered a controlled substance in many countries and is illegal to possess and distribute without proper authorization.
Used in Combination with Other Substances:
TFMPP is often used in combination with other substances to enhance its effects. This practice poses significant health risks and potential for abuse, as the combination can lead to unpredictable and dangerous outcomes.

InChI:InChI=1/C13H20N2O2/c1-16-10-11-17-13-4-2-12(3-5-13)15-8-6-14-7-9-15/h2-5,14H,6-11H2,1H3

Upstream product

• 110-85-0 piperazine 
• 39255-23-7 1-Bromo-4-(2-Methoxyethoxy)-benzene 
• 158985-25-2 tert-butyl 4-(4-hydroxyphenyl)piperazine-1-carboxylate 
• 106-41-2 4-bromo-phenol 
• 67914-60-7 N-acetyl-N'-(4-hydroxyphenyl)piperazine 
• 387358-27-2 1-{4-[4-(2-methoxy-ethoxy)-phenyl]-piperazin-1-yl}-ethanone 

Downstream Products

• 850648-57-6 C₁₉H₂₆N₆O₂ 
• 1135433-94-1 C₁₅H₂₃ClN₂O₂ 
• 1135433-95-2 2-(4-(4-(2-methoxyethoxy)phenyl)piperazin-1-yl)ethan-1-ol 

Relevant articles and documents

PYRAZOLOTRIAZOLOPYRIMIDINE DERIVATIVES AS A2A RECEPTOR ANTAGONIST

Disclosed herein is a pyrazolotriazolopyrimidine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof useful as A2A receptor antagonist, and a pharmaceutical composition comprising the same. Also disclosed herein is a method of treating cancer using the pyrazolotriazolopyrimidine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof as A2A receptor antagonist.

Fluorinated adenosine A2A receptor antagonists inspired by preladenant as potential cancer immunotherapeutics

Antagonism of the adenosine A2A receptor on T cells blocks the hypoxia-adenosinergic pathway to promote tumor rejection. Using an in vivo immunoassay based on the Concanavalin A mouse model, a series of A2A antagonists were studied and identified preladenant as a potent lead compound for development.Molecular modeling was employed to assist drug design and subsequent synthesis of analogs and those of tozadenant, including fluorinated polyethylene glycol PEGylated derivatives. The efficacy of the analogs was evaluated using two in vitro functional bioassays, and compound 29, a fluorinated triethylene glycol derivative of preladenant, was confirmed as a potential immunotherapeutic agent.

3H-[1,2,4]-Triazolo[5,1-i]purin-5-amine derivatives as adenosine A2A antagonists

A novel series of 3-substituted-8-aryl-[1,2,4]-triazolo[5,1-i]purin-5-amine analogs related to Sch 58261 was synthesized in order to identify potent adenosine A2A receptor antagonists with improved selectivity over the A1 receptor, physiochemical properties, and pharmacokinetic profiles as compared to those of Sch 58261. As a result of structural modifications, numerous analogs with excellent in vitro binding affinities and selectivities were identified. Moreover, compound 27 displayed both superior in vitro and highly promising in vivo profiles.

Potent, selective, and orally active adenosine A2A receptor antagonists: Arylpiperazine derivatives of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines

Antagonism of the adenosine A2A receptor offers great promise in the treatment of Parkinson's disease. Employing the known pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine A2A antagonist SCH 58261 as a starting point, we identified the potent and selective (vs. A1) antagonist 11 h, orally active in the rat haloperidol-induced catalepsy model. We further optimized this lead to the methoxyethoxyethyl ether 12a (SCH 420814), which shows broad selectivity, good pharmacokinetic properties, and excellent in vivo activity.

2-(2-Furanyl)-7-phenyl[1,2,4]triazolo[1,5-c]pyrimidin-5-amine analogs: Highly potent, orally active, adenosine A2A antagonists. Part 1

The structure-activity relationship of this novel class of compounds based on 2-(2-furanyl)-7-phenyl[1,2,4]-triazolo[1,5-c]pyrimidin-5-amine, 1, and its analogs was evaluated for their in vitro and in vivo adenosine A2A receptor antagonism. Several compounds displayed oral activity at 3 mg/kg in a rat catalepsy model. Specifically, compound 8g displayed an excellent in vitro profile, as well as a highly promising in vivo profile.